Involvement of the ubiquitin-proteasome pathway in the degradation of nontyrosine kinase-type cytokine receptors of IL-9, IL-2, and erythropoietin

被引:47
作者
Yen, CH
Yang, YC
Ruscetti, SK
Kirken, RA
Dai, RM
Li, CCH
机构
[1] NCI, Frederick Canc Res & Dev Ctr, Intramural Res Support Program, Sci Applicat Int Corp, Frederick, MD 21702 USA
[2] NCI, Frederick Canc Res & Dev Ctr, Div Basic Sci, Basic Res Lab, Frederick, MD 21702 USA
[3] Indiana Univ, Sch Med, Dept Med & Biochem Mol Biol, Indianapolis, IN 46202 USA
[4] Univ Texas, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA
关键词
D O I
10.4049/jimmunol.165.11.6372
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The ubiquitin-dependent proteasome-mediated (Ub-Pr) degradation pathway has been shown to regulate a large variety of substrates, including nuclear, cytosolic, and membrane proteins. In mammalian systems, polyubiquitin modification has been identified in a number of cell surface receptors for more than a decade; however, its biological significance has remained unclear until recently, For growth factor receptors vith intrinsic tyrosine kinase domains, polyubiquitination is believed to trigger the internalization and subsequent degradation via the lysosomal pathway, In this study we provide the first evidence that non-tyrosine kinase-type cytokine surface receptors, IL-9R alpha -chain, IL-2 receptor beta -chain, and erythropoietin receptor, can be polyubiquitinated and degraded by proteasomes. The Ub-Pr pathway regulates both the basal level turnover and the ligand-induced degradation of the receptors, A previously identified putative molecular chaperon, valosin-containing protein, undergoes tyrosine phosphorylation in a cytokine dependent manner and associates with the receptor complexes following receptor engagement, suggesting that valosin-containing protein may target the ubiquitinated receptors to the proteasome for degradation.
引用
收藏
页码:6372 / 6380
页数:9
相关论文
共 47 条
[1]   The proteasome:: Paradigm of a self-compartmentalizing protease [J].
Baumeister, W ;
Walz, J ;
Zühl, F ;
Seemuller, E .
CELL, 1998, 92 (03) :367-380
[2]   The proteasome [J].
Bochtler, M ;
Ditzel, L ;
Groll, M ;
Hartmann, C ;
Huber, R .
ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE, 1999, 28 :295-+
[3]   Ubiquitin and the control of protein fate in the secretory and endocytic pathways [J].
Bonifacino, JS ;
Weissman, AM .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1998, 14 :19-57
[4]   Degradation of proto-oncoprotein c-Rel by the ubiquitin-proteasome pathway [J].
Chen, E ;
Hrdlickova, R ;
Nehyba, J ;
Longo, DL ;
Bose, HR ;
Li, CCH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (52) :35201-35207
[5]   The ubiquitin-proteasome pathway: on protein death and cell life [J].
Ciechanover, A .
EMBO JOURNAL, 1998, 17 (24) :7151-7160
[6]   Structure and functions of the 20S and 26S proteasomes [J].
Coux, O ;
Tanaka, K ;
Goldberg, AL .
ANNUAL REVIEW OF BIOCHEMISTRY, 1996, 65 :801-847
[7]   Involvement of valosin-containing protein, an ATPase co-purified with IκBα and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IκBα [J].
Dai, RM ;
Chen, EY ;
Longo, DL ;
Gorbea, CM ;
Li, CCH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (06) :3562-3573
[8]  
DAMELL JE, 1997, SCIENCE, V277, P1630
[9]  
DANDREA A, 1990, INT J CELL CLONING S, V1, P173
[10]   VCP, THE MAMMALIAN HOMOLOG OF CDC48, IS TYROSINE PHOSPHORYLATED IN RESPONSE TO T-CELL ANTIGEN RECEPTOR ACTIVATION [J].
EGERTON, M ;
ASHE, OR ;
CHEN, D ;
DRUKER, BJ ;
BURGESS, WH ;
SAMELSON, LE .
EMBO JOURNAL, 1992, 11 (10) :3533-3540